PLOD1 and neoplasm: Our results show that an effective domain order of bsDbs is retained after Fc fusion, and that hEx3-scDb-Fc-LH, and especially its IgG2 variant, are attractive candidates for next-generation therapeutic antibodies with potent anti-tumor effects, degradation resistance, long half-lives, and a low risk of side effects.